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Li-Chen Tang1, Xi Jin1, Hai-Yuan Yang1, Min He1, Helena Chang2, Zhi-Ming Shao1 and Gen-Hong Di1*Abstract
Background: The prognoses of young breast cancer patients are poor. The purpose of this study is to evaluate the
different characteristics and prognoses among different subtypes of young breast cancer patients.
Methods: The study included 1360 patients <40 years-old (y) and 3110 patients 40-50y with operable breast cancer
in Shanghai Cancer Center, Fudan University. The characteristics, overall survival (OS) and disease-free survival (DFS)
were compared.
Results: The median follow-up was 54.1 months. More grade III tumors and more lymph-vascular invasions (P <
0.01) were presented in <40y group when compared with 40-50y group. More patients <40y presented with
Luminal B (25.3% vs. 17.5%, P < 0.01) and triple negative (16.7% vs. 13.4%, P < 0.05) breast cancer while fewer had
Luminal A tumor (48.5% vs. 59.2%, P < 0.01). Younger patients with tumors of both Luminal A and Luminal B types
were at increased risk for worse DFS (P = 0.03, HR = 1.69, 95% CI = 1.05-2.72; P < 0.01, HR = 3.61, 95% CI = 2.50-5.22)
when compared with the older patients. Patients <40y with Luminal B tumor had a two point five fold higher risk
of death compared with older counterparts (P < 0.01, HR = 2.54, 95% CI = 1.35-4.79), however, a worse overall
survival rate was not observed in the younger women with Luminal A breast cancer (P > 0.05). In multivariate
analysis, Luminal B subtype was also a strong predictor of disease relapse (HR = 1.09, 95% CI = 1.01 to 1.19, P < 0.01)
in younger patients with Luminal subtype tumors.
Conclusion: Characteristics of breast cancer suggested a more aggressive biology in Chinese patients with breast
cancer diagnosed at young age. Luminal B subtype may have a negative effect on the prognosis of young patients
in China which should be validated further.
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Breast cancer is the most common cancer in women in
developed countries. According to the American Cancer
Society, there will be over 200,000 new breast cancer pa-
tients in the USA in 2010, accounting for 28% of all ma-
lignant tumors in women [1]. It was estimated that only
11% of breast cancer patients are diagnosed between 35-
44 years of age (y); and less than 5% are diagnosed under
the age of 35 [2]. However, the figure reported is signifi-
cantly higher in Asian, especially in Chinese population* Correspondence: zhimingshao@yahoo.com
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unless otherwise stated.(10-20% in total) [3,4]. Breast cancer, although rare in
young women, in known to have more aggressive bio-
logical characteristics and is associated with a more un-
favorable prognosis compared with older women [4-6]. As
previous reported, it is known that 5-year overall survival
(OS) of young breast cancer patients was 80-90% and 5-
year disease-free survival (DFS) was 70-80%, which were
significantly lower than their older counterparts [7].
However, not all young breast cancer patients suffered
from poor prognosis. To date, few well-designed study
have focused on young age breast cancer and breast can-
cer subtypes. Although there is still no clear definition of
‘young’ breast cancer patients (ranging from 30 y to 45 y),
the relationship of young breast cancer patients and breasthis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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purpose of this study is to evaluate the different character-
istics and prognoses among different subtypes of breast
cancer between young breast cancer patients aged 39 or
younger and the patients aged 40-50.
Methods
Patients and follow-up
The medical records of 2138 and 4747 female patients
aged <40y and 40-50y who had breast cancer diagnosed
first time and were treated with breast surgery between
Jan 1st, 2003 and December 31st, 2012, were retrospect-
ively reviewed. This study was approved by the Ethics
Committee of Shanghai Cancer Hospital, Fudan Univer-
sity. The information was retrieved from the database of
the Shanghai Cancer Center, Fudan University, Shanghai,
China. All patients were staged according to the 2007
American Joint Committee on Cancer (AJCC) guidelines
[8,9]. Seven hundred and seventy-eight and 1637 pa-
tients were excluded from the two groups respectively
according to the inclusion and exclusion criteria listed in
Figure 1. Patients who required neoadjuvant therapy or
who had metastastic disease were not included. Clinical
and pathologic characteristics of these patients were
classified by the inpatients’ computerised database, as re-
quired by the REMARK criteria [10,11]. All patients were
required to have a complete physical examination, bilateral
mammography, chest radioscopy, ECG, ultrasonography
of breasts, axillary fossa, cervical parts, abdomen and pel-
vis, and routine blood and biochemical tests before sur-
gery and adjuvant therapy when appropriate. OutpatientFigure 1 CONSORT diagram of inclusion criteria and exclusion
criteria for study.department records and records of personal contact with
the patients, including routine correspondence and/or
telephone calls, were used to follow the patients and deter-
mine the occurrence of loco-regional recurrence, distant
metastasis or death. Patients returned to the Shanghai
Cancer Center, Fudan University for follow-up every
3 months during the first 2 years, every 6 months in the
third to fifth years, and annually after 5 years.
Standard treatment
All patients were required to have a comprehensive phys-
ical examination and a pre-operative evaluation before
surgery. All of the mastectomies and lumpectomies were
R0 resection (margin-clear resection). Treatment with ad-
juvant chemotherapy, post-mastectomy radiotherapy and/
or endocrine therapy was determined by the risk of relapse
and was based on the standard of care at the time of sur-
gery. Immunohistochemical (IHC) staining was used to
evaluate the status of estrogen receptors (ER) and proges-
terone receptors (PR) in the tumors, as previously de-
scribed. HER2 status was evaluated by IHC staining with
(3+) being positive, (0 and 1+) being negative and (2+) re-
quiring further evaluated by FISH. Four subtypes were de-
fined: 1) Luminal A: ER(+) and/or PR(+), HER2(-), grade 1
or grade 2 tumors, 2) Luminal B: ER(+) and/or PR(+) and
HER2(+) tumors or ER(+) and /or PR(+) and HER2(-)
grade 3 tumors, 3) HER2+: ER(-), PR(-) and HER2(+) tu-
mors, 4) Triple negative: ER-, PR-,HER2- tumors.
Endpoints and statistical analysis
Overall survival (OS) was defined as the time from the
first diagnosis of primary breast cancer to death from
any cause. Disease-free survival (DFS) was defined as the
time from the diagnosis of breast cancer to the develop-
ment of any local recurrence or metastatic disease. Pa-
tients without any evidence of relapse or death were
censored at the last date they were known to be alive.
Statistical analysis was carried out with SPSS, version
16.0 (SPSS Inc, Chicago, IL). The Chi-square test was
used to compare patient and clinical-pathological char-
acteristics between sub-groups, and the nonparametric
Kruskal–Wallis rank test was used for ordinal categor-
ical variables. Survival distributions were estimated by
the Kaplan–Meier method, and the comparison between
subgroups was done by the log-rank test. Multivariate
analysis was carried out using Cox’s proportional hazard
regression model, and hazard ratios (HR) are presented
with their 95% confidence intervals. All statistical tests
were two sided, and P < 0.05 was considered significant.
Results and discussion
Clinicopathologic characteristics
One thousand three hundred and sixty patients below
the age of 40y and 3110 patients from 40y to 50y with
Table 1 Clinicopathologic characteristics of patients
according to age
Age <40y 40 ~ 50y P value
character No. % No. %
T stage <0.01
T1 520 38.2 1072 34.5
T2 625 46.0 1914 56.3
T3 215 15.8 124 9.2
N stage 0.07
N0 626 46.0 1580 50.8
N1 324 23.8 787 25.3
N2 324 23.8 606 19.5
N3 86 6.4 137 4.4
Family history <0.01
Yes 80 5.9 44 1.4
No 1280 94.1 3066 98.6
Tumor Grade <0.01
Grade I 56 4.1 93 3.0
Grade II 775 57 2233 71.8
Grade III 529 38.9 784 25.2
Tumor type 0.4
IDC 1216 89.4 2762 88.8
ILC 60 4.4 168 5.4
Others 84 6.2 180 5.8
LVI <0.01
Positive 413 30.4 790 25.4
Negative 947 69.6 2320 74.6
ER status <0.01
Positive 821 60.4 2133 68.6
Negative 539 39.6 977 31.4
PR status 0.9
Positive 826 60.7 1894 60.9
Negative 534 39.3 1216 39.1
HER2 status 0.01
Positive 390 28.7 647 20.8
Negative 970 71.3 2463 79.2
Subtype <0.01
Luminal A 660 48.5 1959 59.2
Luminal B 344 25.3 579 17.5
Her2 positive 129 9.5 327 9.9
Triple negative 227 16.7 445 13.4
Srugery <0.01
BCS 223 16.4 236 7.6
Mastectomy 1137 83.6 2874 92.4
Table 1 Clinicopathologic characteristics of patients
according to age (Continued)
Endocrine therapy 0.7
No 204 15.0 442 14.2
Yes 1156 85 2668 85.8
Chemotherapy 0.4
No 92 6.8 308 9.9
Yes 1268 93.2 2802 90.1
Radiotherapy 0.1
No 1020 75.0 2568 82.6







BCS breast conservative surgery.
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patient characteristics of the two groups were summa-
rized in Table 1. The median age was 35.2y and 46.0y re-
spectively for the two comparison groups. Eighty
patients (5.9%) younger than 40y had a family history in
comparison with 1.4% in the group of 40-50y patients
(P < 0.05). Two hundred and twenty-three (16.4%) pa-
tients aged 39 or younger received breast conservative
surgery (BCS) while fewer older patients (7.6%) under-
went BCS. A larger proportion of younger patients re-
ceived chemotherapy (93.2% vs. 90.1%) and radiotherapy
(25% vs. 17.4%). However, the difference were not statis-
tically significant in all adjuvant therapies between the
two groups (P > 0.05, Table 1).
Younger patients tended to have a higher T stage (P <
0.01) and the trend of a higher N stage (P = 0.07) in com-
parison with the group of older patients. More grade III tu-
mors (38.9% vs. 25.2%, P < 0.01) and more lymph-vascular
invasions (30.4% vs. 25.4%, P < 0.01) were presented in
the <40y group when compared with 40-50y group.
Breast cancer in women younger than 40 had a lower
ER positive rate (60.4% vs. 68.6%, P < 0.01) but a higher
HER2 positive rate (28.7% vs. 20.8%, P < 0.01) between
the pair. The PR positive rate was similar between the
two groups (P = 0.9). More patients <40y presented Lu-
minal B (25.3% vs. 17.5%, P < 0.01) and triple negative
(16.7% vs. 13.4%, P < 0.05) breast cancer while less of
them presented Luminal A tumor (48.5% vs. 59.2%, P <
0.01, Table 1). The percentage of patients with HER2
positive, hormone receptor negative breast cancer was
similar in both groups (9.0% vs. 9.9%, P > 0.05, Table 1).
When the cut-off age was set at 35y, almost the same
characteristics as women aged 39 or younger were found
with more of these patients having family history of breast
cancer and BCS. Similarly, tumor of patients <35y
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lymph-vascular invasions. The proportion of Luminal B
and triple negative breast cancer in <35y patients was also
preponderant over that in 35-50y patients (Data not
shown).
When we analyzed the subtypes according to molecu-
lar classification, more patients with HER2+ and Triple
negative breast cancer presented higher T and N stage in
comparison with those with Luminal groups (P < 0.05).
There was no significant difference in surgical modality
or adjuvant therapy strategy among the four subtype
groups (P > 0.05,data not shown).
Survival analysis
The median follow-up of the reported patients was
54.1 months (58.8 months for <40y group vs.
50.5 months for 40-51y group). The 5y DFS was 72% vs.
83% (P < 0.01) and the 5y OS was 87% vs. 93% (P < 0.01),
in favour of patients in the 40-50y group (Figure 2A,B).
There were significant differences between the two age
groups with regards to the ascending of T stage and N
stage subgroups (P < 0.01 both for OS and DFS, data not
shown). The survival curves of the <40y group fell more
sharply as the tumor grade increased when compared with
women of older age group (P < 0.01 both for OS and DFS,
data not shown). The effect of age on survival was signifi-
cantly different between <40y group and 40-50y group, ad-
justed for tumor size and/or lymph node status (P < 0.01,
HR = 1.64, 95% CI = 1.13-2.38 for OS and P < 0.01, HR =
2.04, 95% CI = 1.62-2.58 for DFS, Figure 2).
When compared different subtypes of breast cancer in
the two different age groups (adjusted T and N stage in
the analysis),younger patients with tumors classified as Lu-
minal A and Luminal B type were at increased risk of poor
DFS (P = 0.03, HR = 1.69, 95% CI = 1.05-2.72; P < 0.01, HR
= 3.61, 95% CI = 2.50-5.22). Additionally, patients <40yFigure 2 Overall survival (A) and disease-free survival (B) of <40y gro
lymph node status. HR, hazard ratio.with Luminal B tumor had a two point five fold higher risk
of death compared with older counterpart (HR = 2.54,
95% CI = 1.35-4.79, Figure 3) while there was no signifi-
cant risk of death associated with Luminal A subgroup
(P > 0.05). In contrast, HER2+ and triple negative breast
cancer showed no significant differences in DFS or OS be-
tween the younger and the older groups (P > 0.05,
Figure 3). Furthermore, Luminal B subtype was a strong
prognostic factor of disease relapse (HR = 1.09, 95% CI =
1.01 to 1.19, P < 0.01) in younger patients with Luminal
subtype tumor.
Almost all the same trends were identified when com-
paring the <35y and ≥35y groups for subgroup compari-
sons as those found when comparing the two groups <40y
and 40-50. Young age was shown being one of the major
predictors for worse survival with respect to the larger
tumour size group, the higher lymph node rate group and
the Luminal B group.Discussion
Breast cancer is a rrare in young women [12,13]. Con-
sensus has been reached that breast cancer in young age
is different from those of less young age [14]. Young pa-
tients often present with more aggressive biologic behav-
ior, such as advanced stage, less ER positive expression,
higher histological grade and more lymph-vascular
invasion [15].
To our acknowledgement, this is the only study focused
on breast cancer subtype and survival with largest sample
of young patients. The most common surgery was mastec-
tomy with axillary lymph node dissection (83.6%) while
breast conserving surgery was performed in only 16.4%
patients. Studies have shown that young age alone is not a
contraindication for breast conservation, but the risks
should be discussed with the patient [16,17].up vs. 41-50y group. *Adjusted for tumor size (≤5 cm v >5 cm) and
Figure 3 Overall survival (A,C,E,G) and disease-free survival (B,D,F,H) between the two age groups, according to subtype (A/B: Luminal
A, C/D: Luminal B, E/F: HER2, Triple negative: G/H). *Adjusted for tumor size (≤5 cm v >5 cm) and lymph node status. HR, hazard ratio.
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tients are found at a more advanced stage and have
more aggressive histologic and molecular characteristics,
irrespective of the cut-off age at 35y or 40y. Younger pa-
tients frequently suffered from a higher T stage, a higher
N stage andmore de-differentiation, which are all indica-
tive of a poorer prognosis . In addition, this study is also
consistent with the results of the Colleoni et al [12] that
more vessel invasions and HER2 overexpresed tumors
were more frequently found in breast cancer occurred in
patients of young age. It was reported that approxi-
mately one-quarter of all breast cancer cases are hor-
mone receptor negative, but a large proportion of
hormone receptor negative tumor occurs in younger
women [18]. Our study showed that younger patients
had fewer hormone receptor-positive cancer (60%) in
comparison with older women group aged between 40-
50 (68%). These data are consistent with previous studies
from other countries reporting less hormone receptor
positivity in younger breast cancer patients [19].
Although environmental, lifestyle and genetic factors
may have a great impact on the survival of young breast
cancer patients, the TNM stage and biological features
determine the prognosis. In our study, we found at a
more advanced stage and have more aggressive histo-
logic and molecular characteristics, irrespective of the
cut-off age at 35y or 40y. Even in multivariate analysis,
young age was a key point to both DFS and OS.
In this study, we found that Luminal A, Luminal B
were the most common subtype in Chinese young breast
cancer patients, followed by triple negative and HER2
positive with negative hormone receptor subtypes.
Others reported that the Luminal B and triple negative
were the most common subtypes in young patients be-
cause of the different definition of breast cancer subtype
which associated with a increased risk of death in young
patients [20]. In our study, young patients with Luminal
B breast cancer had a 2.5 fold higher risk of death and
3.6 fold higher risk of relapse disease compared with the
older counterpart Luminal A, HER2+ or triple negative,
had similar survival outcomes in the two age groups.
These findings were supported by recent studies re-
ported by Chang’s group [21]. This finding has the ac-
cordance with the report of Lin et al [22]. Our study and
others suggest that HER2 over-expression, high tumor
grade and hormone receptor status may all be important
prognostic factors in young breast cancer patients. Hor-
mone receptor positivity may be important in managing
young breast cancer patients because of the long expos-
ure to the high level of estrogen [23]. Therefore, patients
of young age with Luminal B tumor defined by positivity
of both hormone receptors and HER2 expression will
benefit from the combination of anti–HER2 target ther-
apy, endocrine therapy and chemotherapy.Our study also has some limitations in clearly defining
young women breast cancer. Some of our cases had very
limited follow-up which were censored too early, which
might influence the survival analysis. Additionally, it is
known that young breast cancer has a disproportionately
high presentation of BRCA1 and BRCA2 mutations
[24,25]. However, genetic testing has not been well
established in China. Further genetic and genomic inves-
tigations may accelerate our understanding of breast
cancer in young patients. Lastly, the definitions of sub-
types of breast cancer varied in the literature which
could mislead the analysis and therefore conclusions.
More reliable classification is needed to better address
the tumor biology in young women’s breast cancer.
Conclusion
In conclusion, tumors in young women are more likely to
present advanced disease with high grade and lymphovas-
cular invasion. Young breast cancer patients in China are
more likely to have Luminal B and triple negative tumor.
Young patients with Luminal B tumor, but not other sub-
type, had the highest risk for relapse and death events over
the older patients. Further research is required to investi-
gate new treatment strategies in young patients with
breast cancer, especially Luminal B subtype.
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